INTS - Intensity Therapeutics Inc

7.52
-0.060   -0.798%

Share volume: 41,302
Last Updated: 03-03-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.31%

PREVIOUS CLOSE
CHG
CHG%
$7.58
-0.06
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
34%
Profitability 35%
Dept financing 31%
Liquidity 50%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-1.83%
1 Month
2,079.08%
3 Months
1,533.72%
6 Months
2,639.53%
1 Year
240.27%
2 Year
63.83%
Key data
Stock price
$7.52
P/E Ratio 
0.00
DAY RANGE
$6.90 - $7.52
EPS 
-$0.75
52 WEEK RANGE
$0.19 - $8.06
52 WEEK CHANGE
$224.14
MARKET CAP 
11.421 M
YIELD 
N/A
SHARES OUTSTANDING 
60.065 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
1.47
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$78,519
AVERAGE 30 VOLUME 
$1,117,473
Company detail
CEO: Lewis H. Bender
Region: US
Website: intensitytherapeutics.com
Employees: 2
IPO year: 2023
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Intensity Therapeutics, Inc. is a clinical stage biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction leading to anti-cancer immune activation. Our new approach involves the direct injection into tumors of a unique product created from our DfuseRx℠ discovery platform. Our principal executive offices are located at 61 Wilton Road, 3rd Floor, Westport, CT.

Recent news